ArticleAntimicrobial agents and chemotherapy2007
Experimental phage therapy against Staphylococcus aureus in mice.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 301 citations in OpenAlex.
- Antibiotic susceptibility of Staphylococcus aureus isolated from subclinical bovine mastitis cases and in vitro efficacy of bacteriophage.Veterinary research communications · 2018Trial
- Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 AgainstViruses · 2026Article
- Effect of Bacteriophage Administration Route on Phage Localization in a Rat MRSA Implant-Associated Infection Model.Antibiotics (Basel, Switzerland) · 2026Article
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-ResistantMicroorganisms · 2026Review
- Phage Therapy in Plant Disease Management: 110 Years of History, Current Challenges, and Future Trends.Plants (Basel, Switzerland) · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.Frontiers in cellular and infection microbiology · 2026Review
- Comparative antibacterial activity of N-terminal and C-terminal domains of a recombinant endolysin againstApplied and environmental microbiology · 2025Article
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- Mapping and Harmonization of CVX vaccine terms to the Vaccine Ontology.bioRxiv : the preprint server for biology · 2025Article
- Article
- A novel Enterococcus faecalis bacteriophage Ef212: biological and genomic features.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review.Frontiers in cellular and infection microbiology · 2025Review
- Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Deep learning-guided structural analysis of a novel bacteriophage KPP105 against multidrug-resistantComputational and structural biotechnology journal · 2025Article
- Beyond Antibiotics: Exploring the Potential of Bacteriophages and Phage Therapy.PHAGE (New Rochelle, N.Y.) · 2024Review
- Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo.Nature communications · 2024Article
- The stability of Staphylococcal bacteriophage in presence of local vancomycin concentrations used in clinical practice.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study describes a bacteriophage (M(Sa)) active against Staphylococcus aureus, including methicillin-resistant staphylococcal strains. When inoculated into mice simultaneously with S. aureus A170 (10(8) CFU/mouse), phage (10(9) PFU) rescued 97% of the mice; when applied to nonlethal (5 x 10(6) CFU/mouse) 10-day infections, the phage also fully cleared the bacteria. The phage M(Sa), delivered inside macrophages by S. aureus, kills the intracellular staphylococci in vivo and in vitro. The phage can also prevent abscess formation and reduce the bacterial load and weight of abscesses. These results suggest a potential use of the phage for the control of both local and systemic human S. aureus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.